共 35 条
- [1] SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancerJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Johnson, GeoffreyLengyelova, EvaNordquist, LukePrasad, VikasAnderson, MoniqueGervasio, OthonParker, MichelleMiller, Robert M.Sartor, A. OliverTagawa, Scott T.
- [2] SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancerJOURNAL OF NUCLEAR MEDICINE, 2024, 65Johnson, GeoffreyLengyelova, EvaNordquist, LukePrasad, VikasAnderson, MoniqueGervasio, OthonParker, MichelleMiller, RobertSartor, OliverTagawa, Scott
- [3] Treatment of metastatic castrate-resistant prostate cancer patient with two cycles of 67Cu-SAR-bisPSMA (8 GBq) leads to complete response (RECIST) and undetectable PSA level: A case reportEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S249Gervasio, O.Nordquist, L.
- [4] COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS247 - TPS247Nordquist, Luke T.Lengyelova, EvaAlmaguel, FrankisMancini, Brandon RobertSong, HongArmstrong, Andrew J.Zurita, Amado J.Anderson, MoniqueParker, MichelleMiller, Robert M.Iagaru, Andrei
- [5] A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancerBMC UROLOGY, 2017, 17Kim, Hae SuLee, Ji YunLee, Su JinLim, Ho YeongSung, Hyun HwanJeon, Hwang GyunJeong, Byong ChangSeo, Seong IlJeon, Seong SooLee, Hyun MooChoi, Han-YongPark, Se Hoon
- [6] A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancerBMC Urology, 17Hae Su KimJi Yun LeeSu Jin LeeHo Yeong LimHyun Hwan SungHwang Gyun JeonByong Chang JeongSeong Il SeoSeong Soo JeonHyun Moo LeeHan-Yong ChoiSe Hoon Park
- [7] A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)Vaishampayan, Ulka N.Narayan, VivekWise, DavidLang, Joshua MichaelLowentritt, Benjamin H.Mellado, BegonaCarles, JoanSaez, M. IsabelAbida, WassimTaplin, Mary-EllenAzad, ArunWang, KarrieBarbash, OlenaFerron-Brady, GeraldineFecteau, DougKhaled, Ahmed HusseinDhar, ArindamDe Bono, Johann S.
- [8] Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC)JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Beltran, H.Vallabhajosula, S.Kelly, W. K.Whang, Y. E.Osborne, J.Petrillo, K.Goldsmith, S. J.Bander, N. H.Nanus, D. M.Tagawa, S. T.
- [9] Non-enrichment-based method for analysis of androgen receptor expression in circulating tumor cells (CTCs) in patients with metastatic castrate-resistant prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)Gross, Mitchell E.Lazar, DanielCho, Edward H.Luttgen, MadelynMetzner, ThomasUson, Maria LoressaTorrey, Melissa LouiseKuhn, Peter
- [10] A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′-Diindolylmethane) in castrate-resistant, non-metastatic prostate cancerAMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2010, 2 (04): : 402 - 411Heath, Elisabeth I.Heilbrun, Lance K.Li, JingVaishampayan, UlkaHarper, FelicityPemberton, PamSarkar, Fazlul H.